Yuhan Corporation (KRX:000100)
South Korea
· Delayed Price · Currency is KRW 96,100
-3,200 (-3.22%)
Last updated: Mar 9, 2026, 2:46 PM KST
Yuhan Revenue
Yuhan had revenue of 570.01B KRW in the quarter ending September 30, 2025, a decrease of -4.80%. This brings the company's revenue in the last twelve months to 2.14T, up 6.36% year-over-year. In the year 2024, Yuhan had annual revenue of 2.07T with 11.23% growth.
Revenue (ttm)
2,136.67B
Revenue Growth
+6.36%
P/S Ratio
3.35
Revenue / Employee
1.03B
Employees
2,067
Market Cap
7,163.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,067.79B | 208.81B | 11.23% |
| Dec 31, 2023 | 1,858.98B | 83.14B | 4.68% |
| Dec 31, 2022 | 1,775.85B | 88.04B | 5.22% |
| Dec 31, 2021 | 1,687.81B | 67.95B | 4.19% |
| Dec 31, 2020 | 1,619.87B | 139.51B | 9.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hanmi Pharm. | 1,466.18B |
| Hanall Biopharma | 154.05B |
| Celltrion Pharm | 274.73B |
| Daewoong Pharmaceutical | 1,541.65B |
| GC Biopharma | 1,934.38B |
| Chong Kun Dang Pharmaceutical | 1,680.99B |
| Ildong Pharmaceutical | 575.66B |
| Daewoong | 2,055.93B |